HIV-1新发感染快速检测技术研究
|
摘要
研究背景
用于估算HIV-1新发感染率的实验室检测技术已有十多年的发展,其中大部分方法都是基于血清学的抗体检测。目前普遍使用的BED和亲和力等基于酶联免疫的方法均需要配备相应的实验设备,熟练的实验操作人员,并且需要若干小时得到实验结果。为了解决这些问题,研究一种可快速准确地进行新发感染检测的方法显得很有必要。斑点金免疫渗滤(Dot immunogold filtration assay, DIGFA)技术是胶体金免疫技术与固相膜相结合的一项快速检测技术,因其快速、简便、经济、结果直观等特点而得到广泛的发展和应用。本文尝试建立了基于金标银染免疫渗滤技术的可对样本同时进行HIV-1常规抗体和新发感染快速检测的方法,以期为节省新发感染检测成本、提高检测效率提供可靠的工具。
研究目的
一、建立可同时对样本进行HW-1常规抗体和新发感染快速检测的方法；
二、研究快速方法应用于HIV-1新发感染检测的窗口期参数；
三、研究快速方法应用于HIV-1新发感染检测的假近期感染率参数；
四、评价快速方法检测HIV-1抗体和新发感染的可行性及适用性,与现有的商品化试剂检测结果进行对比,为开发用于HIV-1新发感染快速检测的有效方法提供技术平台。
研究方法
一、以HIV-1M组多亚型基因重组gp41抗原(Recombinant immunodominant region of gp41of HIV-1group M, rIDR-M)和普通重组HIV-1gp41抗原作为探针包被硝酸纤维素膜分别用以检测HIV-1新发感染和常规抗体,胶体金标记的抗人IgG作为显色试剂,通过银染进一步增强反应信号,建立快速检测方法并进行初步验证；
二、通过检测250份血清学系列阳转样本(62名血清学阳转感染者),利用SPSS17.0软件对汇总数据进行统计分析,获得快速方法应用于新发感染检测的窗口期参数；
三、通过对256例已知为长期感染(感染时间大于1年)并且未进行抗逆转录病毒治疗的感染者样本的检测,计算快速方法应用于新发感染检测的假近期感染率参数；
四、对比582例样本的新发感染检测结果,比较所建立的快速检测方法与BED方法、限制性抗原亲和力方法的符合率、一致性和相关性；85例样本HIV-1抗体检测结果与WB确认实验的结果进行对比,观察其符合率与一致性。
研究结果
一.rIDR-M和普通gp41抗原分别以15.3μg/ml和500μg/ml作为包被浓度效果最佳,银染试剂用量为50μ1染色时间为3分钟时反应信号最强,确定两个探针的Cutoff值分别为3.50和4.08；建立的快速方法检测5例已知感染时间的阳性样本和1例阴性样本的判定结果全部正确,批内和批间的重复实验分析探针灰度值的变异系数均小于15%,方法具有较好的重复性。
二、取rIDR-M抗原探针的Cutoff-3.50,新发感染快速检测方法的窗口期为189天；抗病毒治疗会对快速方法的检测结果产生一定的影响。
三、快速检测方法的假近期感染率为2.73％(7/256,95％CI0.73%-4.73%),CD4+T淋巴细胞计数对快速方法检测结果的影响不大。
四、快速方法检测新发感染与BED方法的符合率为92.10%(536/582),一致性和相关性均较好(Kappa=0.65,R2=0.9397),与限制性抗原亲和力方法的符合率为95.36%(555/582),且具有很好的一致性和相关性(Kappa=0.75,R2=0.9549)；快速方法检测HIV-1抗体与WB实验结果完全一致,其阳性符合率和阴性符合率均达到了100%。
研究结论
一、通过对反应体系的优化、各检测探针Cutoff值的确定及结果判定标准的制定,建立了基于金标银染免疫渗滤技术的可同时对样本进行HIV-1常规抗体和新发感染快速检测的方法。
二、初步获得快速方法用于HIV-1新发感染检测的窗口期参数为189天。
三、初步获得快速方法用于新发感染检测的假近期感染率参数为2.73%,该方法的假近期感染率高于限制性抗原亲和力方法低于BED方法。
四、构建的快速检测方法对样本进行新发感染检测与BED和限制性抗原亲和力方法检测结果相比均具有较好的一致性和相关性,快速方法检测HIV-1抗体与WB实验结果对比具有非常高的符合率,该方法可为HIV-1新发感染的现场检测和实验室初筛提供可靠、高效的工具。
Background
The development of laboratory assays for the estimation of recent HTV-1infection has more than ten years, most of the assays are based on serological antibody detection. Nowadays, the commonly used methods such as BED-CEIA and avidity assay require standard immunoassay equipment, highly trained personnel and several hours to complete. In order to solve these problems, it is necessary to develop a rapid and accurate method for detection of HIV-1incidence. Dot immunogold filtration assay (DIGFA) is a rapid detection technology which combines the immunogold technology and the solid-phase membrane. With the characteristics of rapid, convenient, economical and visualized, DIGFA has been widely developed and applied. In this study, a rapid HIV test based on immuno-gold-silver staining filtration assay for simultaneous detection of recent HIV-1infection and HIV-1conventional antibody was established, hoping to provide a reliable tool for saving the cost and improve the efficiency of detection of HIV-1incidence.
Objectives
1. To establish a rapid test for simultaneous detection of HIV-1conventional antibody and recent infection.
2. To obtain the mean duration of recent HIV-1infection of the rapid test for incidence calculation.
3. To obtain the false recent rate of the rapid test for incidence calculation.
4. To evaluate the feasibility and applicability of the rapid test for detection of HIV-1conventional antibody and recent infection, and compare with the existing commercial assays, for providing a technical platform for development of effective method for rapid detection of HIV-1incidence.
Methods
1. Nitrocellulose membranes were coated by a multisubtype HIV-1gp41recombinant protein (Recombinant immunodominant region of gp41of HIV-1group M, rIDR-M) and common HIV-1gp41recombinant protein for detecting recent HIV-1infection and conventional antibody, respectively. Gold-labeled anti-human IgG conjugate was used as a detection antibody and silver staining was taken for further enhancing the reaction signal, by which the rapid test was established and preliminary assessed.
2. Two hundred and fifty seroconversional specimens from two cohort studies (62seroconvertors) were tested and the data was analyzed using SPSS17.0to obtain the mean duration of recency of the rapid test.
3. Two hundred and fifty six long-term infection (diagnosed time longer than one year) and antiretroviral therapy naive specimens were tested to calculate the false recent rate of the rapid test.
4. Recent infection testing results of582specimens were compared and the agreement, concordance and correlation of the rapid test with BED-CEIA and LAg-Avidity EIA were evaluated. HIV-1antibody testing results of85specimens were compared and the agreement and concordance of the rapid test with western blot results were observed.
Results
1. The optimal coating concentration of the rIDR-M and common HIV-1gp41recombinant protein was15.3μg/ml and500μg/ml, respectively. When the dosage of the silver staining reagent was50μl and stained for3minutes, the reaction signal got the strongest. The cutoff value of the two probes was3.50and4.08, respectively. The testing results of5positive specimens with seroconversion date and one negative specimen by the rapid test were all correct. The rapid test showed favourable repeatability with coefficient of variation of each probe less than15%.
2. When the cutoff value of the rapid test was3.50, the mean duration of recency of this assay was189days. The antiretroviral therapy could affect the results of the rapid test.
3. The false recent rate of the rapid test was2.73%(7/256,95%CI0.73%-4.73%), and CD4+T cell counts could not affect the results of the rapid test.
4. There was a92.10%(536/582) agreement of final classification (recent or long-term) with the BED assay (kappa=0.65) and a high correlation between the grey value of the rIDR-M probe with the BED ODn (R2=0.9397). While there was a95.36%(555/582) agreement of final classification with the LAg-Avidity EIA (kappa=0.75) and a high correlation between the grey value of the rIDR-M probe with the LAg-Avidity ODn (R2=0.9549). The HIV-1antibody testing results of the rapid test and western blot were in full accord, and the coincidence rates of both positive and negative specimens were100%.
Conclusions
1. Through the optimization of reaction system, determination of the cutoff value of each probe and development the interpretative criteria of the testing results, a rapid HIV test based on immuno-gold-silver staining filtration assay for simultaneous detection of HIV-1conventional antibody and recent HIV-1infection was established.
2. Preliminary obtain the mean duration of recent HIV-1infection of the rapid test was189days.
3. Preliminary obtain the false recent rate of the rapid test was2.73%, higher than the false recent rate of the LAg-Avidity EIA and lower than the false recent rate of the BED assay.
4. The concordance and correlation of the rapid test with the BED assay and LAg-Avidity EIA for detection of recent infection was satisfactory. There was a high agreement of HIV-1antibody testing results between the rapid test and western blot test. The method described in this study could be a reliable and high-efficiency tool for the field detection and laboratory screening of recent HIV-1infection.
用于估算HIV-1新发感染率的实验室检测技术已有十多年的发展,其中大部分方法都是基于血清学的抗体检测。目前普遍使用的BED和亲和力等基于酶联免疫的方法均需要配备相应的实验设备,熟练的实验操作人员,并且需要若干小时得到实验结果。为了解决这些问题,研究一种可快速准确地进行新发感染检测的方法显得很有必要。斑点金免疫渗滤(Dot immunogold filtration assay, DIGFA)技术是胶体金免疫技术与固相膜相结合的一项快速检测技术,因其快速、简便、经济、结果直观等特点而得到广泛的发展和应用。本文尝试建立了基于金标银染免疫渗滤技术的可对样本同时进行HIV-1常规抗体和新发感染快速检测的方法,以期为节省新发感染检测成本、提高检测效率提供可靠的工具。
研究目的
一、建立可同时对样本进行HW-1常规抗体和新发感染快速检测的方法；
二、研究快速方法应用于HIV-1新发感染检测的窗口期参数；
三、研究快速方法应用于HIV-1新发感染检测的假近期感染率参数；
四、评价快速方法检测HIV-1抗体和新发感染的可行性及适用性,与现有的商品化试剂检测结果进行对比,为开发用于HIV-1新发感染快速检测的有效方法提供技术平台。
研究方法
一、以HIV-1M组多亚型基因重组gp41抗原(Recombinant immunodominant region of gp41of HIV-1group M, rIDR-M)和普通重组HIV-1gp41抗原作为探针包被硝酸纤维素膜分别用以检测HIV-1新发感染和常规抗体,胶体金标记的抗人IgG作为显色试剂,通过银染进一步增强反应信号,建立快速检测方法并进行初步验证；
二、通过检测250份血清学系列阳转样本(62名血清学阳转感染者),利用SPSS17.0软件对汇总数据进行统计分析,获得快速方法应用于新发感染检测的窗口期参数；
三、通过对256例已知为长期感染(感染时间大于1年)并且未进行抗逆转录病毒治疗的感染者样本的检测,计算快速方法应用于新发感染检测的假近期感染率参数；
四、对比582例样本的新发感染检测结果,比较所建立的快速检测方法与BED方法、限制性抗原亲和力方法的符合率、一致性和相关性；85例样本HIV-1抗体检测结果与WB确认实验的结果进行对比,观察其符合率与一致性。
研究结果
一.rIDR-M和普通gp41抗原分别以15.3μg/ml和500μg/ml作为包被浓度效果最佳,银染试剂用量为50μ1染色时间为3分钟时反应信号最强,确定两个探针的Cutoff值分别为3.50和4.08；建立的快速方法检测5例已知感染时间的阳性样本和1例阴性样本的判定结果全部正确,批内和批间的重复实验分析探针灰度值的变异系数均小于15%,方法具有较好的重复性。
二、取rIDR-M抗原探针的Cutoff-3.50,新发感染快速检测方法的窗口期为189天；抗病毒治疗会对快速方法的检测结果产生一定的影响。
三、快速检测方法的假近期感染率为2.73％(7/256,95％CI0.73%-4.73%),CD4+T淋巴细胞计数对快速方法检测结果的影响不大。
四、快速方法检测新发感染与BED方法的符合率为92.10%(536/582),一致性和相关性均较好(Kappa=0.65,R2=0.9397),与限制性抗原亲和力方法的符合率为95.36%(555/582),且具有很好的一致性和相关性(Kappa=0.75,R2=0.9549)；快速方法检测HIV-1抗体与WB实验结果完全一致,其阳性符合率和阴性符合率均达到了100%。
研究结论
一、通过对反应体系的优化、各检测探针Cutoff值的确定及结果判定标准的制定,建立了基于金标银染免疫渗滤技术的可同时对样本进行HIV-1常规抗体和新发感染快速检测的方法。
二、初步获得快速方法用于HIV-1新发感染检测的窗口期参数为189天。
三、初步获得快速方法用于新发感染检测的假近期感染率参数为2.73%,该方法的假近期感染率高于限制性抗原亲和力方法低于BED方法。
四、构建的快速检测方法对样本进行新发感染检测与BED和限制性抗原亲和力方法检测结果相比均具有较好的一致性和相关性,快速方法检测HIV-1抗体与WB实验结果对比具有非常高的符合率,该方法可为HIV-1新发感染的现场检测和实验室初筛提供可靠、高效的工具。
Background
The development of laboratory assays for the estimation of recent HTV-1infection has more than ten years, most of the assays are based on serological antibody detection. Nowadays, the commonly used methods such as BED-CEIA and avidity assay require standard immunoassay equipment, highly trained personnel and several hours to complete. In order to solve these problems, it is necessary to develop a rapid and accurate method for detection of HIV-1incidence. Dot immunogold filtration assay (DIGFA) is a rapid detection technology which combines the immunogold technology and the solid-phase membrane. With the characteristics of rapid, convenient, economical and visualized, DIGFA has been widely developed and applied. In this study, a rapid HIV test based on immuno-gold-silver staining filtration assay for simultaneous detection of recent HIV-1infection and HIV-1conventional antibody was established, hoping to provide a reliable tool for saving the cost and improve the efficiency of detection of HIV-1incidence.
Objectives
1. To establish a rapid test for simultaneous detection of HIV-1conventional antibody and recent infection.
2. To obtain the mean duration of recent HIV-1infection of the rapid test for incidence calculation.
3. To obtain the false recent rate of the rapid test for incidence calculation.
4. To evaluate the feasibility and applicability of the rapid test for detection of HIV-1conventional antibody and recent infection, and compare with the existing commercial assays, for providing a technical platform for development of effective method for rapid detection of HIV-1incidence.
Methods
1. Nitrocellulose membranes were coated by a multisubtype HIV-1gp41recombinant protein (Recombinant immunodominant region of gp41of HIV-1group M, rIDR-M) and common HIV-1gp41recombinant protein for detecting recent HIV-1infection and conventional antibody, respectively. Gold-labeled anti-human IgG conjugate was used as a detection antibody and silver staining was taken for further enhancing the reaction signal, by which the rapid test was established and preliminary assessed.
2. Two hundred and fifty seroconversional specimens from two cohort studies (62seroconvertors) were tested and the data was analyzed using SPSS17.0to obtain the mean duration of recency of the rapid test.
3. Two hundred and fifty six long-term infection (diagnosed time longer than one year) and antiretroviral therapy naive specimens were tested to calculate the false recent rate of the rapid test.
4. Recent infection testing results of582specimens were compared and the agreement, concordance and correlation of the rapid test with BED-CEIA and LAg-Avidity EIA were evaluated. HIV-1antibody testing results of85specimens were compared and the agreement and concordance of the rapid test with western blot results were observed.
Results
1. The optimal coating concentration of the rIDR-M and common HIV-1gp41recombinant protein was15.3μg/ml and500μg/ml, respectively. When the dosage of the silver staining reagent was50μl and stained for3minutes, the reaction signal got the strongest. The cutoff value of the two probes was3.50and4.08, respectively. The testing results of5positive specimens with seroconversion date and one negative specimen by the rapid test were all correct. The rapid test showed favourable repeatability with coefficient of variation of each probe less than15%.
2. When the cutoff value of the rapid test was3.50, the mean duration of recency of this assay was189days. The antiretroviral therapy could affect the results of the rapid test.
3. The false recent rate of the rapid test was2.73%(7/256,95%CI0.73%-4.73%), and CD4+T cell counts could not affect the results of the rapid test.
4. There was a92.10%(536/582) agreement of final classification (recent or long-term) with the BED assay (kappa=0.65) and a high correlation between the grey value of the rIDR-M probe with the BED ODn (R2=0.9397). While there was a95.36%(555/582) agreement of final classification with the LAg-Avidity EIA (kappa=0.75) and a high correlation between the grey value of the rIDR-M probe with the LAg-Avidity ODn (R2=0.9549). The HIV-1antibody testing results of the rapid test and western blot were in full accord, and the coincidence rates of both positive and negative specimens were100%.
Conclusions
1. Through the optimization of reaction system, determination of the cutoff value of each probe and development the interpretative criteria of the testing results, a rapid HIV test based on immuno-gold-silver staining filtration assay for simultaneous detection of HIV-1conventional antibody and recent HIV-1infection was established.
2. Preliminary obtain the mean duration of recent HIV-1infection of the rapid test was189days.
3. Preliminary obtain the false recent rate of the rapid test was2.73%, higher than the false recent rate of the LAg-Avidity EIA and lower than the false recent rate of the BED assay.
4. The concordance and correlation of the rapid test with the BED assay and LAg-Avidity EIA for detection of recent infection was satisfactory. There was a high agreement of HIV-1antibody testing results between the rapid test and western blot test. The method described in this study could be a reliable and high-efficiency tool for the field detection and laboratory screening of recent HIV-1infection.
引文
[1]Jiang Y, Wang M, Ni M, et al. HIV-1 incidence estimates using IgG-capture BED-enzyme immunoassay from surveillance sites of injection drug users in three cities of China. AIDS.2007,21 Suppl 8:S47-S51.
[2]陶钧,孟令章,肖瑶.HIV-1发病率研究方法及其比较.中国艾滋病性病.2011,17(2)：191-195.
[3]于海英,蒋岩,王宇.用于HIV新发感染检测的亲和力方法的研究进展.中国艾滋病性病.2012,18(8)：575-578.
[4]Parekh BS, McDougal JS. New approaches for detecting recent HIV-1 infection. AIDS Rev.2001,3:183-193.
[5]Busch MP, Pilcher CD, Mastro TD, et al. Beyond detuning:10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS.2010,24(18):2763-2771.
[6]Mastro TD, Kim AA, Hallett T, et al. Estimating HIV incidence in populations using tests for recent infection:issues, challenges and the way forward. J HIV AIDS Surveill Epidemiol.2010,2(1):1-14.
[7]Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA.1998,280(1):42-48.
[8]肖瑶,冯基刚,蒋岩.用于HIV感染早期监测及发病率调查的实验室检测技术·——STARHS检测法.中华流行病学杂志.2005,26(7)：544-546.
[9]蒋岩,汪宁.中国艾滋病实验室网络发展20年.2009,北京,北京科学技术出版社：83-86.
[10]Le Vu S, Pillonel J, Semaille C, et al. Principles and uses of HIV incidence estimation from recent infection testing--a review. Euro Surveill.2008,13(36). pii:18969.
[11]Parekh BS, McDougal JS. Application of laboratory methods for estimation of HIV-1 incidence. Indian J Med Res.2005,121(4):510-518.
[12]Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill.2008,13(7-9):4-10.
[13]Saphonn V, Parekh BS, Dobbs T, et al. Trends of HIV-1 seroincidence among HIV-1 sentinel surveillance groups in Cambodia,1999-2002. J Acquir Immune Defic Syndr.2005,39(5):587-592.
[14]Xiao Y, Jiang Y, Feng J, et al. Seroincidence of recent human immunodeficiency virus type 1 infections in China. Clin Vaccine Immunol.2007,14:1384-1386.
[15]Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA.2008,300:520-529.
[16]Hargrove JW, Humphrey JH, Mutasa K, et al. Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS.2008,22: 511-518.
[17]Kim AA, McDougal JS, Hargrove J, et al. Evaluating the BED capture enzyme immunoassay to estimate HIV incidence among adults in three countries in sub-Saharan Africa. AIDS Res Hum Retroviruses.2010,26:1051-1061.
[18]Duan S, Shen S, Bulterys M, et al. Estimation of HIV-1 incidence among five focal populations in Dehong, Yunnan:a hard hit area along a major drug trafficking route. BMC Public Health.2010,10:180.
[19]Wolday D, Meles H, Hailu E, et al. Temporal trends in the incidence of HIV infection in antenatal clinic attendees in Addis Ababa, Ethiopia,1995-2003. J Intern Med.2007,261(2):132-137.
[20]Parekh BS, Kennedy MS, Dobbs T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion:a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses.2002,18: 295-307.
[21]Dobbs T, Kennedy S, Pau CP, et al. Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol.2004,42: 2623-2628.
[22]Chawla A, Murphy G, Donnelly C, et al. Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1) -seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol.2007,45(2):415-420.
[23]Wei X, Liu X, Dobbs T, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses.2010,26(1):61-71.
[24]Duong YT, Qiu MF, De AK, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay:potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One.2012,7(3):e33328.
[25]于海英LAg-Avidity EIA用于中国HIV-1新发感染率估算的适用性研究.中国疾病预防控制中心.2013.
[26]Soroka SD, Granade TC, Candal D, et al. Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion. Clin Diagn Lab Immunol.2005,12(8):918-921.
[27]Kshatriya R, Cachafeiro AA, Kerr RJ, et al. Comparison of two rapid human immunodeficiency virus (HIV) assays, Determine HIV-1/2 and OraQuick Advance Rapid HIV-1/2, for detection of recent HIV seroconversion. J Clin Microbiol.2008,46(10):3482-3483.
[28]Granade TC, Nguyen S, Kuehl DS, et al. Development of a novel rapid HIV test for simultaneous detection of recent or long-term HIV type 1 infection using a single testing device. AIDS Res Hum Retroviruses.2013,29(1):61-67.
[29]张宏刚,宋玲玲,陈苏红.斑点金免疫渗滤技术及其在检测中的应用.军事医学.2011,35(4)：307-309.
[30]Spielberg F, Kabeya CM, Ryder RW, et al. Field testing and comparative evaluation of rapid, visually read screening assays for antibody to human immunodeficiency virus. Lancet.1989,1(8638):580-584.
[31]翟建新,王业富,段炼炼,等.应用斑点金免疫渗滤试验快速同步检测抗HIV-1, HIV-2 IgG抗体.中国病毒学.2006,21(2)：116-120.
[32]Huang Q, Lan X, Tong T, et al. Dot-immunogold filtration assay as a screening test for syphilis. J Clin Microbiol.1996,34(8):2011-2013.
[33]Han FC, Hou Y, Yan XJ, et al. Dot immunogold filtration assay for rapid detection of anti-HAV IgM in Chinese. World J Gastroenterol.2000,6(3): 400-401.
[34]Zhang A, Zhang M, Zhang H, et al. Development of a dot-immunoenzyme filtration assay for the detection of enterovirus 71 antigen in human serum via immunoglobulin M. J Int Med Res.2012,40(3):1122-1129.
[35]Jin M, Lang J, Shen ZQ, et al. A rapid subtractive immunization method to prepare discriminatory monoclonal antibodies for food E. coli O157:H7 contamination. PLoS One.2012,7(2):e31352.
[36]Wen LY, Chen JH, Ding JZ, et al. Evaluation on the applied value of the dot immunogold filtration assay (DIGFA) for rapid detection of anti-Schistosoma japonicum antibody.Acta Trop.2005,96(2-3):142-147.
[37]Feng X, Wen H, Zhang Z, et al. Dot immunogold filtration assay (DIGFA) with multiple native antigens for rapid serodiagnosis of human cystic and alveolar echinococcosis.Acta Trop.2010,113(2):114-120.
[38]Ye Y, Zhou Y, Mo Z, et al. Rapid detection of aflatoxin B(1) on membrane by dot-immunogold filtration assay. Talanta.2010,81(3):792-798.
[39]Cao YC, Jin R, Mirkin CA. Nanoparticles with Raman spectroscopic fingerprints for DNA and RNA detection. Science.2002,297(5586):1536-1540.
[40]颜浩.免疫规划疫苗抗体检测蛋白芯片的研制.中国人民解放军军事医学科学院.2011.
[41]Wang X, Zhan W, Xing J. Development of dot-immunogold filtration assay to detect white spot syndrome virus of shrimp. J Virol Methods.2006,132(1-2): 212-215.
[42]Busch MP, Pilcher CD, Mastro TD, et al. Beyond detuning:10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS.2010,24(18):2763-2771.
[43]沈圣,蒋岩.HIV新近感染检测方法研究进展.中华流行病学杂志.2010,31(4)：462-465.
[44]张娜,蒋岩.HIV新发感染检测方法研究进展.国际病毒学杂志.2013,20(2)：76-80.
[45]Dobbs T, Liu X, Anderson R, et al. A comprehensive evaluation of the proficiency testing program for the HIV-1 BED incidence assay. J Clin Microbiol. 2011,49:3470-3473.
[46]中国疾病预防控制中心性病艾滋病预防控制中心.艾滋病病毒抗体快速检测技术手册(2011版).2011.
[47]张宏刚.金标银染免疫渗滤法检测土拉弗朗西斯菌的方法建立及应用.山西医科大学.2011.
[48]宋玲玲.两种快速检测病原体方法的建立及应用.中国人民解放军军医进修学院.2012.
[49]国务院办公厅.中国遏制与防治艾滋病“十二五”行动计划[EB/OL]. http://www.china.com.cn/policy/txt/2012-03/01/content_24767662.htm. 2012-01-13.
[50]McFarland W, Busch M P, Kellogg T A, et al. Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr.1999,22(5):484-489.
[51]Kothe D, Byers RH, Caudill SP, et al. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr.2003,33(5):625-634.
[52]Suligoi B, Massi M, Galli C, et al. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr.2003,32(4):424-428.
[53]Suligoi B, Galli C, Massi M, et al. Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. J Clin Microbiol.2002,40(11):4015-4020.
[54]中国疾病预防控制中心性病艾滋病预防控制中心.HIV-1新发感染血清学方法检测方案(试行).2011.
[55]中国疾病预防控制中心性病艾滋病预防控制中心.性艾中心二○一三年全国艾滋病病毒抗体诊断试剂临床质量评估报告[EB/OL]. http://ww.chinacdc.cn/gwswxx/xazx/201311/t20131112_90108.htm. 2013-11-11.
[56]中国疾病预防控制中心性病艾滋病预防控制中心.中国疾控中心性艾中心2012年全国艾滋病病毒抗体诊断试剂临床质量评估报告[EB/OL]. http://www.chinaids.org.cn/fwxx/ggb/201301/t20130110_75445.htm. 2012-11-14.
[57]中国疾病预防控制中心性病艾滋病预防控制中心.性艾中心2011年全国HIV抗体诊断试剂临床质量评估报告[EB/OL]. http://www.chinacdc.cn/gwswxx/xazx/201111/t20111108_54678.htm. 2011-11-08.
[58]UNAIDS/World Health Organization (WHO). When and how to use assays for recent infection to estimate HIV incidence at a population level [EB/OL]. http://www.who.int/diagnostics_laboratory/110906_guidance_hiv_incidence.pdf. 2011.
[59]沈圣.HIV-1新发感染检测应用研究.中国疾病预防控制中心.2010.
[60]Parekh BS, Hanson DL, Hargrove J, et al. Determination of mean recency period for estimation of HIV type 1 incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses.2011,27(3): 265-273.
[61]Sharma UK, Schito M, Welte A, et al. Workshop summary:Novel biomarkers for HIV incidence assay development. AIDS Res Hum Retroviruses.2012,28(6): 532-539.
[62]Parekh BS, Hu DJ, Vanichseni S, et al. Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion, among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Res Hum Retroviruses.2001,17:453-458.
[63]Lu L, Jia M, Ma Y, et al. The changing face of HIV in China. Nature.2008, 455(7213):609-611.
[64]周衍衡,庞伟,郑永唐.云南省HIV-1分子流行病学研究进展.皮肤病与性病.2010,32(1)：20-23.
[65]杨绍敏,李惠琴,陈立力,等.云南省2008-2009年HIV-1病毒株亚型分布.中华流行病学杂志.2012,33(8)：836-840.
[66]Marinda ET, Hargrove J, Preiser W, et al. Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr.2010,53 (4):496-499.
[67]Hladik W, Olara D, Mermin J, et al. Effect of CD4+ T cell count and antiretroviral treatment on two serological HIV incidence assays. AIDS Res Hum Retroviruses.2012,28(1):95-99.
[68]Jiang Y. Development and challenge of HIV/AIDS testing laboratory network and quality assurance system in China. Virol Sin.2007,22:434-442.
[69]Jiang Y, Qiu M,'Zhang Q et al. Quality assurance in the HIV/AIDS laboratory network of China. Int J Epidemiol.2010,39:ii72-ii78.
[70]Duong YT, Parekh BS. From BED to LAg:Development and Characterization of Limiting-Antigen Avidity EIA. China HIV-1 Incidence Workshop. Kunming, Yunnan, China October 29-30,2013.
[71]Mc Walter TA, Welte A. Relating recent infection prevalence to incidence with a sub-population of assay non-progressors. J Math Biol.2010,60(5):687-710.
[72]Hayashida T, Gatanaga H, Tanuma J, et al. Short Communication:Effects of low HIV type 1 load and antiretroviral treatment on IgG-Capture BED-Enzyme immunoassay. AIDS Res Hum Retroviruses.2008,24(3):495-498.
[73]Hallett TB, Ghys P, Barnighausen T, et al. Errors in'BED'-derived estimates of HIV incidence will vary by place, time and age. PLoS One.2009,4(5):e5720.
[74]陶钧,赵晶,刘勇,等.BED捕获酶免疫试验方法检测HIV-1新发感染的系统评价.中华流行病学杂志.2011,32(2)：177-181.
[75]Mcdougal JS, Parekh BS, Peterson ML, et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses.2006,22(10):945-952.
[76]MP Biomedicals Asia Pacific Pte. Ltd. HIV Blot 2.2 package insert [EB/OL]. http://www.mpbiochina.com/ueditor/net/upload/2013-12-02/ddef05c1-233f-4eb2-afa9-e74ff1b7168c.pdf.2013.
[77]Laeyendecker O, Brookmeyer R, Oliver AE, et al. Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay. AIDS Res Hum Retroviruses.2012,28(8):816-822.
[78]Laeyendecker O, Brookmeyer R, Mullis CE, et al. Specificity of four laboratory approaches for cross-sectional HIV incidence determination:Analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res Hum Retroviruses.2012,28(10):1177-1183.
[79]Karita E, Price M, Hunter E, et al. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS.2007,21(4):403-408.
[80]中国疾病预防控制中心.全国艾滋病检测技术规范(2009年修订版).2009.
[81]Altman DG. Practical statistics for medical research. London:Chapman and Hall. 1991.
[82]Byrt T. How good is that agreement? Epidemiology.1996,7(5):561.
[83]MedMira Laboratories Inc. Rapid HIV Test (Whole Blood) Package Insert [EB/OL]. http://medmira.com/images/uploads/DKIBIS0423_0447_A_CH_EN_Rapid_HIV_B__WB__Format__Triplex___Chinese_English_.pdf.2009.
[84]MedMira Laboratories Inc. Rapid HIV Test (Serum/Plasma) Package Insert [EB/OL]. http://medmira.com/images/uploads/DKIAIS0188_A_CH_EN_Mira Well_HIV_A_Format__Triplex__Chinese_English_.pdf.2009.
[85]董华凰,刘建礼,朱红,等.金纳米探针结合PCR检测HIV-1 p24抗原的研究.中华检验医学杂志.2012,35(5)：448-452.
[86]Dong H, Liu J, Zhu H, et al. Two types of nanoparticle-based bio-barcode amplification assays to detect HIV-1 p24 antigen. Virology journal.2012,9(1): 180.
[87]Beelaert G, Fransen K. Evaluation of a rapid and simple fourth-generation HIV screening assay for qualitative detection of HIV p24 antigen and/or antibodies to HIV-1 and HIV-2. J Virol Methods.2010,168(1-2):218-222.
[88]Chetty V, Moodley D, Chuturgoon A. Evaluation of a 4th generation rapid HIV test for earlier and reliable detection of HIV infection in pregnancy. J Clin Virol. 2012,54(2):180-184.
[89]Rosenberg NE, Kamanga G, Phiri S, et al. Detection of acute HIV infection:a field evaluation of the determine(?) HIV-1/2 Ag/Ab combo test. J Infect Dis.2012, 205(4):528-534.
[90]Kilembe W, Keeling M, Karita E, et al. Failure of a novel, rapid antigen and antibody combination test to detect antigen-positive HIV infection in African adults with early HIV infection. PLoS One.2012,7(6):e37154.
[91]Brauer M, De Villiers JC, Mayaphi SH. Evaluation of the DetermineTM fourth generation HIV rapid assay. J Virol Methods.2013,189(1):180-183.
[92]Faraoni S, Rocchetti A, Gotta F, et al. Evaluation of a rapid antigen and antibody combination test in acute HIV infection. J Clin Virol.2013,57(1):84-87.
[1]World Health Organization. Core epidemiological slides--HIV/AIDS estimates [EB/OL]. http://www.who.int/hiv/data/2013_epi_core.ppt?ua=1.2013.
[2]World Health Organization, United Nations Children's Fund, Joint United Nations Programme on HIV/AIDS. Towards universal access:scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. Geneva, Switzerland:WHO; 2011.
[3]Curioso WH, Kurth AE, Cabello R, et al. Usability evaluation of Personal Digital Assistants (PDAs) to support HIV treatment adherence and safer sex behavior in Peru. AMIA Annu Symp Proc.2008,6:918.
[4]Branson BM. State of the art for diagnosis of HIV infection. Clin Infect Dis.2007, 45(Supplement 4):S221-S225.
[5]Fanales-Belasio E, Raimondo M, Suligoi B, et al. HIV virology and pathogenetic mechanisms of infection:a brief overview. Ann Ist Super Sanita.2010,46(1): 5-14.
[6]Cohen MS, Shaw GM, McMichael AJ, et al. Acute HIV-1 infection. N Engl J Med.2011,364(20):1943-1954.
[7]Weber B. Screening of HIV infection:role of molecular and immunological assays. Expert Rev Mol Diagn.2006,6(3):399-411.
[8]Daskalakis D. HIV diagnostic testing:evolving technology and testing strategies. Top Antivir Med.2011,19(1):18-22.
[9]Butto S, Suligoi B, Fanales-Belasio E, et al. Laboratory diagnostics for HIV infection. Ann Ist Super Sanita.2010,46(1):24-33.
[10]Cohen MS, Dye C, Fraser C, et al. HIV treatment as prevention:debate and commentary--will early infection compromise treatment-as-prevention strategies? PLoS Med.2012,9(7):e1001232.
[11]Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1:virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol.2008,82(24):12449-12463.
[12]Schupbach J, Gebhardt MD, Scherrer AU, et al. Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns. PLoS One.2013,8(8): e71662.
[13]Wilson KM, Johnson El, Croom HA, et al. Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. AIDS.2004,18(17):2253-2259.
[14]Salahuddin SZ, Markham PD, Redfield RR, et al. HTLV-Ⅲ in symptom-free seronegative persons. The Lancet.1984,324(8417):1418-1420.
[15]Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill.2008,13(7-9):4-10.
[16]Giles RE, Perry KR, Parry JV. Simple/rapid test devices for anti-HIV screening: do they come up to the mark? J Med Virol.1999,59(1):104-109.
[17]中国疾病预防控制中心.全国艾滋病检测技术规范(2009年修订版).2009.
[18]Kagulire SC, Stamper PD, Opendi P, et al. Performance of two commercial immunochromatographic assays for rapid detection of antibodies specific to human immunodeficiency virus types 1 and 2 in serum and urine samples in a rural community-based research setting (Rakai, Uganda). Clin Vaccine Immunol. 2007,14(6):738-740.
[19]Taye B, Woldeamanuel Y, Kebede E. Diagnostic detection of human immunodeficincy virus type-1 antibodies in urine, Jimma Hospital, south west Ethiopa. Ethiop Med J.2006,44(4):363-368.
[20]Pascoe SJ, Langhaug LF, Mudzori J, et al. Field evaluation of diagnostic accuracy of an oral fluid rapid test for HIV, tested at point-of-service sites in rural Zimbabwe. AIDS Patient Care STDS.2009,23(7):571-576.
[21]中国疾病预防控制中心性病艾滋病预防控制中心.艾滋病病毒抗体快速检测技术手册(2011版).2011.
[22]中国疾病预防控制中心性病艾滋病预防控制中心.性艾中心二○一三年全国艾滋病病毒抗体诊断试剂临床质量评估报告[EB/OL]. http://www.chinacdc.cn/gwswxx/xazx/201311/t20131112_90108.htm. 2013-11-11.
[23]卓凡,郑红,黄捷玲.三种艾滋病检测试剂的应用与比较.职业与健康.2004,20(5)：40-41.
[24]周志军,丰亮,王润贵,等.明胶颗粒凝集(PA)法检测HIV抗体假阳性因素分析.实验与检验医学.2010,28(6)：627.
[25]符克英,钟娜,张丽芬,等.梅毒患者血清对HIV明胶颗粒凝集试验的影响.中国皮肤性病学杂志.2009,23(8)：507-508.
[26]Ye Y, Zhou Y, Mo Z, et al. Rapid detection of aflatoxin B(1) on membrane by dot-immunogold filtration assay. Talanta.2010,81(3):792-798.
[27]Feng X, Wen H, Zhang Z, et al. Dot immunogold filtration assay (DIGFA) with multiple native antigens for rapid serodiagnosis of human cystic and alveolar echinococcosis.Acta Trop.2010,113(2):114-120.
[28]Delaney KP, Branson BM, Uniyal A, et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis.2011,52(2): 257-263.
[29]中国疾病预防控制中心性病艾滋病预防控制中心.性艾中心2011年全国HIV 抗体诊断试剂临床质量评估报告[EB/OL]. http://www.chinacdc.cn/gwswxx/xazx/201111/t20111108_54678.htm. 2011-11-08.
[30]中国疾病预防控制中心性病艾滋病预防控制中心.中国疾控中心性艾中心2012年全国艾滋病病毒抗体诊断试剂临床质量评估报告[EB/OL]. http://www.chinaids.org.cn/fwxx/ggb/201301/t20130110_75445.htm. 2012-11-14.
[31]Gough E, Edwards P. HIV seroprevalence and associated risk factors among male inmates at the Belize Central Prison. Rev Panam Salud Publica.2009,25(4): 292-299.
[32]Lochhead MJ, Todorof K, Delaney M, et al. Rapid multiplexed immunoassay for simultaneous serodiagnosis of HIV-1 and coinfections. J Clin Microbiol.2011, 49(10):3584-3590.
[33]董华凰,刘建礼,朱红,等.金纳米探针结合PCR检测HIV-1 p24抗原的研究.中华检验医学杂志.2012,35(5)：448-452.
[34]Dong H, Liu J, Zhu H, et al. Two types of nanoparticle-based bio-barcode amplification assays to detect HIV-1 p24 antigen. Virology journal.2012,9(1): 180.
[35]Beelaert G, Fransen K. Evaluation of a rapid and simple fourth-generation HIV screening assay for qualitative detection of HIV p24 antigen and/or antibodies to HIV-1 and HIV-2. J Virol Methods.2010,168(1-2):218-222.
[36]Chetty V, Moodley D, Chuturgoon A. Evaluation of a 4th generation rapid HIV test for earlier and reliable detection of HIV infection in pregnancy. J Clin Virol. 2012,54(2):180-184.
[37]Rosenberg NE, Kamanga G, Phiri S, et al. Detection of acute HIV infection:a field evaluation of the determine(?) HIV-1/2 Ag/Ab combo test. J Infect Dis.2012, 205(4):528-534.
[38]Kilembe W, Keeling M, Karita E, et al. Failure of a novel, rapid antigen and antibody combination test to detect antigen-positive HIV infection in African adults with early HIV infection. PLoS One.2012,7(6):e37154.
[39]Brauer M, De Villiers JC, Mayaphi SH. Evaluation of the DetermineTM fourth generation HIV rapid assay. J Virol Methods.2013,189(1):180-183.
[40]Faraoni S, Rocchetti A, Gotta F, et al. Evaluation of a rapid antigen and antibody combination test in acute HIV infection. J Clin Virol.2013,57(1):84-87.
[41]Jiang Y, Wang M, Ni M, et al. HIV-1 incidence estimates using IgG-capture BED-enzyme immunoassay from surveillance sites of injection drug users in three cities of China. AIDS.2007,21 Suppl 8:S47-S51.
[42]Busch MP, Pilcher CD, Mastro TD, et al. Beyond detuning:10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS.2010,24(18):2763-2771.
[43]Parekh BS, McDougal JS. Application of laboratory methods for estimation of HIV-1 incidence. Indian J Med Res.2005,121(4):510-518.
[44]Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA.1998,280(1):42-48.
[45]Soroka SD, Granade TC, Candal D, et al. Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion. Clin Diagn Lab Immunol.2005,12(8):918-921.
[46]Kshatriya R, Cachafeiro AA, Kerr RJ, et al. Comparison of two rapid human immunodeficiency virus (HIV) assays, Determine HIV-1/2 and OraQuick Advance Rapid HIV-1/2, for detection of recent HIV seroconversion. J Clin Microbiol.2008,46(10):3482-3483.
[47]Li H, Ketema F, Sill AM, et al. A simple and inexpensive particle agglutination test to distinguish recent from established HIV-1 infection. Int J Infect Dis.2007, 11(5):459-465.
[48]李洪,陆林,贾曼红,等BED-CEIA与PA-LS检测HIV-1近期感染的比较性研究.皮肤病与性病.2007,29(3)：1-3.
[49]Granade TC, Nguyen S, Kuehl DS, et al. Development of a novel rapid HIV test for simultaneous detection of recent or long-term HIV type 1 infection using a single testing device. AIDS Res Hum Retroviruses.2013,29(1):61-67.
[1]Jiang Y, Wang M, Ni M, et al. HIV-1 incidence estimates using IgG-capture BED-enzyme immunoassay from surveillance sites of injection drug users in three cities of China[J]. AIDS. 2007,21 Suppl 8:S47-S51.
[2]Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1[J]. Euro Surveill.2008,13(7-9):4-10.
[3]Parekh BS, McDougal JS. Application of laboratory methods for estimation of HIV-1 incidence[J]. Indian J Med Res.2005,121(4):510-518.
[4]Yan H, Yu H, Xing W, et al. Development of a proficiency testing program for the HIV-1 BED incidence assay in China[J]. Sci Rep.2014,4:4512.
[5]Chawla A, Murphy G, Donnelly C, et al. Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes[J]. J Clin Microbiol.2007,45(2):415-420.
[6]Wei X, Liu X, Dobbs T, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein[J]. AIDS Res Hum Retroviruses.2010,26(1):61-71.
[7]翟建新,王业富,段炼炼,等.应用斑点金免疫渗滤试验快速同步检测抗HIV-1,HIV-2IgG抗体[J].中国病毒学,2006,21(2)：116-120.
[8]Zhang A, Zhang M, Zhang H, et al. Development of a dot-immunoenzyme filtration assay for the detection of enterovirus 71 antigen in human serum via immunoglobulin M[J]. J Int Med Res. 2012,40(3):1122-1129.
[9]Feng X, Wen H, Zhang Z, et al. Dot immunogold filtration assay (DIGFA) with multiple native antigens for rapid serodiagnosis of human cystic and alveolar echinococcosis[J].Acta Trop.2010, 113(2):114-120.
[10]于海英,蒋岩,王宇.用于HIV新发感染检测的亲和力方法的研究进展[J].中国艾滋病性病,2012,18(8)：575-578.
[11]张宏刚,宋玲玲,陈苏红.斑点金免疫渗滤技术及其在检测中的应用[J].军事医学,2011,35(4)：307-309.
[12]Duong YT, Qiu MF, De AK, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay:potential for HIV-1 incidence estimates and avidity maturation studies[J]. PLoS One.2012,7(3):e33328.
[13]Soroka SD, Granade TC, Candal D, et al. Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion[J]. Clin Diagn Lab Immunol.2005,12(8):918-921.
[14]Kshatriya R, Cachafeiro AA, Kerr RJ, et al. Comparison of two rapid human immunodeficiency virus (HIV) assays, Determine HIV-1/2 and OraQuick Advance Rapid HIV-1/2, for detection of recent HIV seroconversion[J]. J Clin Microbiol.2008,46(10):3482-3483.
[2]陶钧,孟令章,肖瑶.HIV-1发病率研究方法及其比较.中国艾滋病性病.2011,17(2)：191-195.
[3]于海英,蒋岩,王宇.用于HIV新发感染检测的亲和力方法的研究进展.中国艾滋病性病.2012,18(8)：575-578.
[4]Parekh BS, McDougal JS. New approaches for detecting recent HIV-1 infection. AIDS Rev.2001,3:183-193.
[5]Busch MP, Pilcher CD, Mastro TD, et al. Beyond detuning:10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS.2010,24(18):2763-2771.
[6]Mastro TD, Kim AA, Hallett T, et al. Estimating HIV incidence in populations using tests for recent infection:issues, challenges and the way forward. J HIV AIDS Surveill Epidemiol.2010,2(1):1-14.
[7]Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA.1998,280(1):42-48.
[8]肖瑶,冯基刚,蒋岩.用于HIV感染早期监测及发病率调查的实验室检测技术·——STARHS检测法.中华流行病学杂志.2005,26(7)：544-546.
[9]蒋岩,汪宁.中国艾滋病实验室网络发展20年.2009,北京,北京科学技术出版社：83-86.
[10]Le Vu S, Pillonel J, Semaille C, et al. Principles and uses of HIV incidence estimation from recent infection testing--a review. Euro Surveill.2008,13(36). pii:18969.
[11]Parekh BS, McDougal JS. Application of laboratory methods for estimation of HIV-1 incidence. Indian J Med Res.2005,121(4):510-518.
[12]Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill.2008,13(7-9):4-10.
[13]Saphonn V, Parekh BS, Dobbs T, et al. Trends of HIV-1 seroincidence among HIV-1 sentinel surveillance groups in Cambodia,1999-2002. J Acquir Immune Defic Syndr.2005,39(5):587-592.
[14]Xiao Y, Jiang Y, Feng J, et al. Seroincidence of recent human immunodeficiency virus type 1 infections in China. Clin Vaccine Immunol.2007,14:1384-1386.
[15]Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA.2008,300:520-529.
[16]Hargrove JW, Humphrey JH, Mutasa K, et al. Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS.2008,22: 511-518.
[17]Kim AA, McDougal JS, Hargrove J, et al. Evaluating the BED capture enzyme immunoassay to estimate HIV incidence among adults in three countries in sub-Saharan Africa. AIDS Res Hum Retroviruses.2010,26:1051-1061.
[18]Duan S, Shen S, Bulterys M, et al. Estimation of HIV-1 incidence among five focal populations in Dehong, Yunnan:a hard hit area along a major drug trafficking route. BMC Public Health.2010,10:180.
[19]Wolday D, Meles H, Hailu E, et al. Temporal trends in the incidence of HIV infection in antenatal clinic attendees in Addis Ababa, Ethiopia,1995-2003. J Intern Med.2007,261(2):132-137.
[20]Parekh BS, Kennedy MS, Dobbs T, et al. Quantitative detection of increasing HIV type 1 antibodies after seroconversion:a simple assay for detecting recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses.2002,18: 295-307.
[21]Dobbs T, Kennedy S, Pau CP, et al. Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion. J Clin Microbiol.2004,42: 2623-2628.
[22]Chawla A, Murphy G, Donnelly C, et al. Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1) -seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol.2007,45(2):415-420.
[23]Wei X, Liu X, Dobbs T, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses.2010,26(1):61-71.
[24]Duong YT, Qiu MF, De AK, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay:potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One.2012,7(3):e33328.
[25]于海英LAg-Avidity EIA用于中国HIV-1新发感染率估算的适用性研究.中国疾病预防控制中心.2013.
[26]Soroka SD, Granade TC, Candal D, et al. Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion. Clin Diagn Lab Immunol.2005,12(8):918-921.
[27]Kshatriya R, Cachafeiro AA, Kerr RJ, et al. Comparison of two rapid human immunodeficiency virus (HIV) assays, Determine HIV-1/2 and OraQuick Advance Rapid HIV-1/2, for detection of recent HIV seroconversion. J Clin Microbiol.2008,46(10):3482-3483.
[28]Granade TC, Nguyen S, Kuehl DS, et al. Development of a novel rapid HIV test for simultaneous detection of recent or long-term HIV type 1 infection using a single testing device. AIDS Res Hum Retroviruses.2013,29(1):61-67.
[29]张宏刚,宋玲玲,陈苏红.斑点金免疫渗滤技术及其在检测中的应用.军事医学.2011,35(4)：307-309.
[30]Spielberg F, Kabeya CM, Ryder RW, et al. Field testing and comparative evaluation of rapid, visually read screening assays for antibody to human immunodeficiency virus. Lancet.1989,1(8638):580-584.
[31]翟建新,王业富,段炼炼,等.应用斑点金免疫渗滤试验快速同步检测抗HIV-1, HIV-2 IgG抗体.中国病毒学.2006,21(2)：116-120.
[32]Huang Q, Lan X, Tong T, et al. Dot-immunogold filtration assay as a screening test for syphilis. J Clin Microbiol.1996,34(8):2011-2013.
[33]Han FC, Hou Y, Yan XJ, et al. Dot immunogold filtration assay for rapid detection of anti-HAV IgM in Chinese. World J Gastroenterol.2000,6(3): 400-401.
[34]Zhang A, Zhang M, Zhang H, et al. Development of a dot-immunoenzyme filtration assay for the detection of enterovirus 71 antigen in human serum via immunoglobulin M. J Int Med Res.2012,40(3):1122-1129.
[35]Jin M, Lang J, Shen ZQ, et al. A rapid subtractive immunization method to prepare discriminatory monoclonal antibodies for food E. coli O157:H7 contamination. PLoS One.2012,7(2):e31352.
[36]Wen LY, Chen JH, Ding JZ, et al. Evaluation on the applied value of the dot immunogold filtration assay (DIGFA) for rapid detection of anti-Schistosoma japonicum antibody.Acta Trop.2005,96(2-3):142-147.
[37]Feng X, Wen H, Zhang Z, et al. Dot immunogold filtration assay (DIGFA) with multiple native antigens for rapid serodiagnosis of human cystic and alveolar echinococcosis.Acta Trop.2010,113(2):114-120.
[38]Ye Y, Zhou Y, Mo Z, et al. Rapid detection of aflatoxin B(1) on membrane by dot-immunogold filtration assay. Talanta.2010,81(3):792-798.
[39]Cao YC, Jin R, Mirkin CA. Nanoparticles with Raman spectroscopic fingerprints for DNA and RNA detection. Science.2002,297(5586):1536-1540.
[40]颜浩.免疫规划疫苗抗体检测蛋白芯片的研制.中国人民解放军军事医学科学院.2011.
[41]Wang X, Zhan W, Xing J. Development of dot-immunogold filtration assay to detect white spot syndrome virus of shrimp. J Virol Methods.2006,132(1-2): 212-215.
[42]Busch MP, Pilcher CD, Mastro TD, et al. Beyond detuning:10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS.2010,24(18):2763-2771.
[43]沈圣,蒋岩.HIV新近感染检测方法研究进展.中华流行病学杂志.2010,31(4)：462-465.
[44]张娜,蒋岩.HIV新发感染检测方法研究进展.国际病毒学杂志.2013,20(2)：76-80.
[45]Dobbs T, Liu X, Anderson R, et al. A comprehensive evaluation of the proficiency testing program for the HIV-1 BED incidence assay. J Clin Microbiol. 2011,49:3470-3473.
[46]中国疾病预防控制中心性病艾滋病预防控制中心.艾滋病病毒抗体快速检测技术手册(2011版).2011.
[47]张宏刚.金标银染免疫渗滤法检测土拉弗朗西斯菌的方法建立及应用.山西医科大学.2011.
[48]宋玲玲.两种快速检测病原体方法的建立及应用.中国人民解放军军医进修学院.2012.
[49]国务院办公厅.中国遏制与防治艾滋病“十二五”行动计划[EB/OL]. http://www.china.com.cn/policy/txt/2012-03/01/content_24767662.htm. 2012-01-13.
[50]McFarland W, Busch M P, Kellogg T A, et al. Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr.1999,22(5):484-489.
[51]Kothe D, Byers RH, Caudill SP, et al. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr.2003,33(5):625-634.
[52]Suligoi B, Massi M, Galli C, et al. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr.2003,32(4):424-428.
[53]Suligoi B, Galli C, Massi M, et al. Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. J Clin Microbiol.2002,40(11):4015-4020.
[54]中国疾病预防控制中心性病艾滋病预防控制中心.HIV-1新发感染血清学方法检测方案(试行).2011.
[55]中国疾病预防控制中心性病艾滋病预防控制中心.性艾中心二○一三年全国艾滋病病毒抗体诊断试剂临床质量评估报告[EB/OL]. http://ww.chinacdc.cn/gwswxx/xazx/201311/t20131112_90108.htm. 2013-11-11.
[56]中国疾病预防控制中心性病艾滋病预防控制中心.中国疾控中心性艾中心2012年全国艾滋病病毒抗体诊断试剂临床质量评估报告[EB/OL]. http://www.chinaids.org.cn/fwxx/ggb/201301/t20130110_75445.htm. 2012-11-14.
[57]中国疾病预防控制中心性病艾滋病预防控制中心.性艾中心2011年全国HIV抗体诊断试剂临床质量评估报告[EB/OL]. http://www.chinacdc.cn/gwswxx/xazx/201111/t20111108_54678.htm. 2011-11-08.
[58]UNAIDS/World Health Organization (WHO). When and how to use assays for recent infection to estimate HIV incidence at a population level [EB/OL]. http://www.who.int/diagnostics_laboratory/110906_guidance_hiv_incidence.pdf. 2011.
[59]沈圣.HIV-1新发感染检测应用研究.中国疾病预防控制中心.2010.
[60]Parekh BS, Hanson DL, Hargrove J, et al. Determination of mean recency period for estimation of HIV type 1 incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res Hum Retroviruses.2011,27(3): 265-273.
[61]Sharma UK, Schito M, Welte A, et al. Workshop summary:Novel biomarkers for HIV incidence assay development. AIDS Res Hum Retroviruses.2012,28(6): 532-539.
[62]Parekh BS, Hu DJ, Vanichseni S, et al. Evaluation of a sensitive/less-sensitive testing algorithm using the 3A11-LS assay for detecting recent HIV seroconversion, among individuals with HIV-1 subtype B or E infection in Thailand. AIDS Res Hum Retroviruses.2001,17:453-458.
[63]Lu L, Jia M, Ma Y, et al. The changing face of HIV in China. Nature.2008, 455(7213):609-611.
[64]周衍衡,庞伟,郑永唐.云南省HIV-1分子流行病学研究进展.皮肤病与性病.2010,32(1)：20-23.
[65]杨绍敏,李惠琴,陈立力,等.云南省2008-2009年HIV-1病毒株亚型分布.中华流行病学杂志.2012,33(8)：836-840.
[66]Marinda ET, Hargrove J, Preiser W, et al. Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr.2010,53 (4):496-499.
[67]Hladik W, Olara D, Mermin J, et al. Effect of CD4+ T cell count and antiretroviral treatment on two serological HIV incidence assays. AIDS Res Hum Retroviruses.2012,28(1):95-99.
[68]Jiang Y. Development and challenge of HIV/AIDS testing laboratory network and quality assurance system in China. Virol Sin.2007,22:434-442.
[69]Jiang Y, Qiu M,'Zhang Q et al. Quality assurance in the HIV/AIDS laboratory network of China. Int J Epidemiol.2010,39:ii72-ii78.
[70]Duong YT, Parekh BS. From BED to LAg:Development and Characterization of Limiting-Antigen Avidity EIA. China HIV-1 Incidence Workshop. Kunming, Yunnan, China October 29-30,2013.
[71]Mc Walter TA, Welte A. Relating recent infection prevalence to incidence with a sub-population of assay non-progressors. J Math Biol.2010,60(5):687-710.
[72]Hayashida T, Gatanaga H, Tanuma J, et al. Short Communication:Effects of low HIV type 1 load and antiretroviral treatment on IgG-Capture BED-Enzyme immunoassay. AIDS Res Hum Retroviruses.2008,24(3):495-498.
[73]Hallett TB, Ghys P, Barnighausen T, et al. Errors in'BED'-derived estimates of HIV incidence will vary by place, time and age. PLoS One.2009,4(5):e5720.
[74]陶钧,赵晶,刘勇,等.BED捕获酶免疫试验方法检测HIV-1新发感染的系统评价.中华流行病学杂志.2011,32(2)：177-181.
[75]Mcdougal JS, Parekh BS, Peterson ML, et al. Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res Hum Retroviruses.2006,22(10):945-952.
[76]MP Biomedicals Asia Pacific Pte. Ltd. HIV Blot 2.2 package insert [EB/OL]. http://www.mpbiochina.com/ueditor/net/upload/2013-12-02/ddef05c1-233f-4eb2-afa9-e74ff1b7168c.pdf.2013.
[77]Laeyendecker O, Brookmeyer R, Oliver AE, et al. Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay. AIDS Res Hum Retroviruses.2012,28(8):816-822.
[78]Laeyendecker O, Brookmeyer R, Mullis CE, et al. Specificity of four laboratory approaches for cross-sectional HIV incidence determination:Analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res Hum Retroviruses.2012,28(10):1177-1183.
[79]Karita E, Price M, Hunter E, et al. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS.2007,21(4):403-408.
[80]中国疾病预防控制中心.全国艾滋病检测技术规范(2009年修订版).2009.
[81]Altman DG. Practical statistics for medical research. London:Chapman and Hall. 1991.
[82]Byrt T. How good is that agreement? Epidemiology.1996,7(5):561.
[83]MedMira Laboratories Inc. Rapid HIV Test (Whole Blood) Package Insert [EB/OL]. http://medmira.com/images/uploads/DKIBIS0423_0447_A_CH_EN_Rapid_HIV_B__WB__Format__Triplex___Chinese_English_.pdf.2009.
[84]MedMira Laboratories Inc. Rapid HIV Test (Serum/Plasma) Package Insert [EB/OL]. http://medmira.com/images/uploads/DKIAIS0188_A_CH_EN_Mira Well_HIV_A_Format__Triplex__Chinese_English_.pdf.2009.
[85]董华凰,刘建礼,朱红,等.金纳米探针结合PCR检测HIV-1 p24抗原的研究.中华检验医学杂志.2012,35(5)：448-452.
[86]Dong H, Liu J, Zhu H, et al. Two types of nanoparticle-based bio-barcode amplification assays to detect HIV-1 p24 antigen. Virology journal.2012,9(1): 180.
[87]Beelaert G, Fransen K. Evaluation of a rapid and simple fourth-generation HIV screening assay for qualitative detection of HIV p24 antigen and/or antibodies to HIV-1 and HIV-2. J Virol Methods.2010,168(1-2):218-222.
[88]Chetty V, Moodley D, Chuturgoon A. Evaluation of a 4th generation rapid HIV test for earlier and reliable detection of HIV infection in pregnancy. J Clin Virol. 2012,54(2):180-184.
[89]Rosenberg NE, Kamanga G, Phiri S, et al. Detection of acute HIV infection:a field evaluation of the determine(?) HIV-1/2 Ag/Ab combo test. J Infect Dis.2012, 205(4):528-534.
[90]Kilembe W, Keeling M, Karita E, et al. Failure of a novel, rapid antigen and antibody combination test to detect antigen-positive HIV infection in African adults with early HIV infection. PLoS One.2012,7(6):e37154.
[91]Brauer M, De Villiers JC, Mayaphi SH. Evaluation of the DetermineTM fourth generation HIV rapid assay. J Virol Methods.2013,189(1):180-183.
[92]Faraoni S, Rocchetti A, Gotta F, et al. Evaluation of a rapid antigen and antibody combination test in acute HIV infection. J Clin Virol.2013,57(1):84-87.
[1]World Health Organization. Core epidemiological slides--HIV/AIDS estimates [EB/OL]. http://www.who.int/hiv/data/2013_epi_core.ppt?ua=1.2013.
[2]World Health Organization, United Nations Children's Fund, Joint United Nations Programme on HIV/AIDS. Towards universal access:scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010. Geneva, Switzerland:WHO; 2011.
[3]Curioso WH, Kurth AE, Cabello R, et al. Usability evaluation of Personal Digital Assistants (PDAs) to support HIV treatment adherence and safer sex behavior in Peru. AMIA Annu Symp Proc.2008,6:918.
[4]Branson BM. State of the art for diagnosis of HIV infection. Clin Infect Dis.2007, 45(Supplement 4):S221-S225.
[5]Fanales-Belasio E, Raimondo M, Suligoi B, et al. HIV virology and pathogenetic mechanisms of infection:a brief overview. Ann Ist Super Sanita.2010,46(1): 5-14.
[6]Cohen MS, Shaw GM, McMichael AJ, et al. Acute HIV-1 infection. N Engl J Med.2011,364(20):1943-1954.
[7]Weber B. Screening of HIV infection:role of molecular and immunological assays. Expert Rev Mol Diagn.2006,6(3):399-411.
[8]Daskalakis D. HIV diagnostic testing:evolving technology and testing strategies. Top Antivir Med.2011,19(1):18-22.
[9]Butto S, Suligoi B, Fanales-Belasio E, et al. Laboratory diagnostics for HIV infection. Ann Ist Super Sanita.2010,46(1):24-33.
[10]Cohen MS, Dye C, Fraser C, et al. HIV treatment as prevention:debate and commentary--will early infection compromise treatment-as-prevention strategies? PLoS Med.2012,9(7):e1001232.
[11]Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1:virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol.2008,82(24):12449-12463.
[12]Schupbach J, Gebhardt MD, Scherrer AU, et al. Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns. PLoS One.2013,8(8): e71662.
[13]Wilson KM, Johnson El, Croom HA, et al. Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. AIDS.2004,18(17):2253-2259.
[14]Salahuddin SZ, Markham PD, Redfield RR, et al. HTLV-Ⅲ in symptom-free seronegative persons. The Lancet.1984,324(8417):1418-1420.
[15]Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill.2008,13(7-9):4-10.
[16]Giles RE, Perry KR, Parry JV. Simple/rapid test devices for anti-HIV screening: do they come up to the mark? J Med Virol.1999,59(1):104-109.
[17]中国疾病预防控制中心.全国艾滋病检测技术规范(2009年修订版).2009.
[18]Kagulire SC, Stamper PD, Opendi P, et al. Performance of two commercial immunochromatographic assays for rapid detection of antibodies specific to human immunodeficiency virus types 1 and 2 in serum and urine samples in a rural community-based research setting (Rakai, Uganda). Clin Vaccine Immunol. 2007,14(6):738-740.
[19]Taye B, Woldeamanuel Y, Kebede E. Diagnostic detection of human immunodeficincy virus type-1 antibodies in urine, Jimma Hospital, south west Ethiopa. Ethiop Med J.2006,44(4):363-368.
[20]Pascoe SJ, Langhaug LF, Mudzori J, et al. Field evaluation of diagnostic accuracy of an oral fluid rapid test for HIV, tested at point-of-service sites in rural Zimbabwe. AIDS Patient Care STDS.2009,23(7):571-576.
[21]中国疾病预防控制中心性病艾滋病预防控制中心.艾滋病病毒抗体快速检测技术手册(2011版).2011.
[22]中国疾病预防控制中心性病艾滋病预防控制中心.性艾中心二○一三年全国艾滋病病毒抗体诊断试剂临床质量评估报告[EB/OL]. http://www.chinacdc.cn/gwswxx/xazx/201311/t20131112_90108.htm. 2013-11-11.
[23]卓凡,郑红,黄捷玲.三种艾滋病检测试剂的应用与比较.职业与健康.2004,20(5)：40-41.
[24]周志军,丰亮,王润贵,等.明胶颗粒凝集(PA)法检测HIV抗体假阳性因素分析.实验与检验医学.2010,28(6)：627.
[25]符克英,钟娜,张丽芬,等.梅毒患者血清对HIV明胶颗粒凝集试验的影响.中国皮肤性病学杂志.2009,23(8)：507-508.
[26]Ye Y, Zhou Y, Mo Z, et al. Rapid detection of aflatoxin B(1) on membrane by dot-immunogold filtration assay. Talanta.2010,81(3):792-798.
[27]Feng X, Wen H, Zhang Z, et al. Dot immunogold filtration assay (DIGFA) with multiple native antigens for rapid serodiagnosis of human cystic and alveolar echinococcosis.Acta Trop.2010,113(2):114-120.
[28]Delaney KP, Branson BM, Uniyal A, et al. Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis.2011,52(2): 257-263.
[29]中国疾病预防控制中心性病艾滋病预防控制中心.性艾中心2011年全国HIV 抗体诊断试剂临床质量评估报告[EB/OL]. http://www.chinacdc.cn/gwswxx/xazx/201111/t20111108_54678.htm. 2011-11-08.
[30]中国疾病预防控制中心性病艾滋病预防控制中心.中国疾控中心性艾中心2012年全国艾滋病病毒抗体诊断试剂临床质量评估报告[EB/OL]. http://www.chinaids.org.cn/fwxx/ggb/201301/t20130110_75445.htm. 2012-11-14.
[31]Gough E, Edwards P. HIV seroprevalence and associated risk factors among male inmates at the Belize Central Prison. Rev Panam Salud Publica.2009,25(4): 292-299.
[32]Lochhead MJ, Todorof K, Delaney M, et al. Rapid multiplexed immunoassay for simultaneous serodiagnosis of HIV-1 and coinfections. J Clin Microbiol.2011, 49(10):3584-3590.
[33]董华凰,刘建礼,朱红,等.金纳米探针结合PCR检测HIV-1 p24抗原的研究.中华检验医学杂志.2012,35(5)：448-452.
[34]Dong H, Liu J, Zhu H, et al. Two types of nanoparticle-based bio-barcode amplification assays to detect HIV-1 p24 antigen. Virology journal.2012,9(1): 180.
[35]Beelaert G, Fransen K. Evaluation of a rapid and simple fourth-generation HIV screening assay for qualitative detection of HIV p24 antigen and/or antibodies to HIV-1 and HIV-2. J Virol Methods.2010,168(1-2):218-222.
[36]Chetty V, Moodley D, Chuturgoon A. Evaluation of a 4th generation rapid HIV test for earlier and reliable detection of HIV infection in pregnancy. J Clin Virol. 2012,54(2):180-184.
[37]Rosenberg NE, Kamanga G, Phiri S, et al. Detection of acute HIV infection:a field evaluation of the determine(?) HIV-1/2 Ag/Ab combo test. J Infect Dis.2012, 205(4):528-534.
[38]Kilembe W, Keeling M, Karita E, et al. Failure of a novel, rapid antigen and antibody combination test to detect antigen-positive HIV infection in African adults with early HIV infection. PLoS One.2012,7(6):e37154.
[39]Brauer M, De Villiers JC, Mayaphi SH. Evaluation of the DetermineTM fourth generation HIV rapid assay. J Virol Methods.2013,189(1):180-183.
[40]Faraoni S, Rocchetti A, Gotta F, et al. Evaluation of a rapid antigen and antibody combination test in acute HIV infection. J Clin Virol.2013,57(1):84-87.
[41]Jiang Y, Wang M, Ni M, et al. HIV-1 incidence estimates using IgG-capture BED-enzyme immunoassay from surveillance sites of injection drug users in three cities of China. AIDS.2007,21 Suppl 8:S47-S51.
[42]Busch MP, Pilcher CD, Mastro TD, et al. Beyond detuning:10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS.2010,24(18):2763-2771.
[43]Parekh BS, McDougal JS. Application of laboratory methods for estimation of HIV-1 incidence. Indian J Med Res.2005,121(4):510-518.
[44]Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA.1998,280(1):42-48.
[45]Soroka SD, Granade TC, Candal D, et al. Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion. Clin Diagn Lab Immunol.2005,12(8):918-921.
[46]Kshatriya R, Cachafeiro AA, Kerr RJ, et al. Comparison of two rapid human immunodeficiency virus (HIV) assays, Determine HIV-1/2 and OraQuick Advance Rapid HIV-1/2, for detection of recent HIV seroconversion. J Clin Microbiol.2008,46(10):3482-3483.
[47]Li H, Ketema F, Sill AM, et al. A simple and inexpensive particle agglutination test to distinguish recent from established HIV-1 infection. Int J Infect Dis.2007, 11(5):459-465.
[48]李洪,陆林,贾曼红,等BED-CEIA与PA-LS检测HIV-1近期感染的比较性研究.皮肤病与性病.2007,29(3)：1-3.
[49]Granade TC, Nguyen S, Kuehl DS, et al. Development of a novel rapid HIV test for simultaneous detection of recent or long-term HIV type 1 infection using a single testing device. AIDS Res Hum Retroviruses.2013,29(1):61-67.
[1]Jiang Y, Wang M, Ni M, et al. HIV-1 incidence estimates using IgG-capture BED-enzyme immunoassay from surveillance sites of injection drug users in three cities of China[J]. AIDS. 2007,21 Suppl 8:S47-S51.
[2]Murphy G, Parry JV. Assays for the detection of recent infections with human immunodeficiency virus type 1[J]. Euro Surveill.2008,13(7-9):4-10.
[3]Parekh BS, McDougal JS. Application of laboratory methods for estimation of HIV-1 incidence[J]. Indian J Med Res.2005,121(4):510-518.
[4]Yan H, Yu H, Xing W, et al. Development of a proficiency testing program for the HIV-1 BED incidence assay in China[J]. Sci Rep.2014,4:4512.
[5]Chawla A, Murphy G, Donnelly C, et al. Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes[J]. J Clin Microbiol.2007,45(2):415-420.
[6]Wei X, Liu X, Dobbs T, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein[J]. AIDS Res Hum Retroviruses.2010,26(1):61-71.
[7]翟建新,王业富,段炼炼,等.应用斑点金免疫渗滤试验快速同步检测抗HIV-1,HIV-2IgG抗体[J].中国病毒学,2006,21(2)：116-120.
[8]Zhang A, Zhang M, Zhang H, et al. Development of a dot-immunoenzyme filtration assay for the detection of enterovirus 71 antigen in human serum via immunoglobulin M[J]. J Int Med Res. 2012,40(3):1122-1129.
[9]Feng X, Wen H, Zhang Z, et al. Dot immunogold filtration assay (DIGFA) with multiple native antigens for rapid serodiagnosis of human cystic and alveolar echinococcosis[J].Acta Trop.2010, 113(2):114-120.
[10]于海英,蒋岩,王宇.用于HIV新发感染检测的亲和力方法的研究进展[J].中国艾滋病性病,2012,18(8)：575-578.
[11]张宏刚,宋玲玲,陈苏红.斑点金免疫渗滤技术及其在检测中的应用[J].军事医学,2011,35(4)：307-309.
[12]Duong YT, Qiu MF, De AK, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay:potential for HIV-1 incidence estimates and avidity maturation studies[J]. PLoS One.2012,7(3):e33328.
[13]Soroka SD, Granade TC, Candal D, et al. Modification of rapid human immunodeficiency virus (HIV) antibody assay protocols for detecting recent HIV seroconversion[J]. Clin Diagn Lab Immunol.2005,12(8):918-921.
[14]Kshatriya R, Cachafeiro AA, Kerr RJ, et al. Comparison of two rapid human immunodeficiency virus (HIV) assays, Determine HIV-1/2 and OraQuick Advance Rapid HIV-1/2, for detection of recent HIV seroconversion[J]. J Clin Microbiol.2008,46(10):3482-3483.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |